The FDA has approved pertuzumab (Perjeta, Genentech) for the treatment of patients with HER2-positive metastatic breast cancer. The therapy is intended for use in combination with docetaxel and trastuzumab in patients who have not received prior treatment for their disease with an anti-HER2 therapy or chemotherapy.
Abstract: FDA.
